Amryt seeks to have rare condition drug approved for payment

The Dublin company is in discussion with regulators in Britain and France to have metreleptin, a treatment for abnormal distribution of fat in the body, approved for payment reimbursement

9th August, 2020
Amryt seeks to have rare condition drug approved for payment
Joe Wiley, Amryt's chief executive, said last week that it is in discussions with the National Institute for Health and Care Excellence

Amryt, the Dublin-based rare drug developer, is in talks with medicines regulators in Britain and other European countries to get its treatments approved for payment reimbursement.

Britain is one of the remaining large European markets where metreleptin, a treatment for lipodystrophy, is yet to be approved for payment following its launch last year. The medical condition involves an abnormal distribution of fat in the body.

Joe Wiley, Amryt's chief executive, said last week that it...

Subscribe from just €1 for the first month!

Currency

What's Included

With any subscription you will have access to

  • 971569B3-2C5E-4C45-B798-CEADE16987A8

    Unlimited multi-device access to our iPad, iPhone and Android Apps

  • 099C8662-C57C-42F2-9426-F2F90DF17C8F

    Unlimited access to our eReader library

  • 198AE43B-B9CF-4892-8769-D63C2104BA08

    Exclusive daily insight and opinion seven days a week

  • D8F37B78-25E4-4E4A-A376-4F5789B1564A

    Create alerts to never miss a subject that matters to you

  • B15F2521-37CD-4E02-B898-730A20D39F7F

    Get access to exclusive offers for subscribers on gifts and experiences

  • A564FE02-1AB8-4579-AF9D-BA32A2E5ACA7

    Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine

Share this post

Related Stories

‘I always had entrepreneurial ambitions and this was first-hand evidence of an unmet need’

PM Group reports 30% profits increase and announces 200 new jobs in Ireland

Neuromod Devices to double Irish headcount within next year

Chanelle founder invests €100k in Redesdale Group